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ABSTRACT
Purpose: We evaluated longitudinal tracking of BRAF V600E in circulating cell-
free DNA (cfDNA) as a marker of treatment response to BRAF inhibitor (BRAFi) 
combination therapies in non-melanoma solid tumors included in the Copenhagen 
Prospective Personalized Oncology (CoPPO) program.
Experimental design: Patients with BRAF V600E-mutated tumors were treated 
with combination therapies including BRAFi. Quantification of mutant cfDNA from 
plasma was determined and correlated to clinical outcomes. Exome sequencing was 
performed to identify possible resistance mutations.
Results: Twenty-three patients had BRAF-mutated tumors out of 455 patients 
included in CoPPO and 17 started BRAFi combination (EGFRi/MEKi) therapy. Tumor 
responses were achieved in 8 out of 16 evaluable patients and the median overall- 
and progression-free survival (OS and PFS) was 15 and 4.8 months, respectively. 
Longitudinal measurements of BRAF V600E-mutant cfDNA indicated disease 
progression prior to radiological evaluation and a reduction in the mutant fraction of 
more than 50% after 4 and 12 weeks of therapy was associated with a significantly 
longer PFS (p=0.003 and p=0.029) and OS (p=0.029 and p=0.017). Furthermore, 
the baseline mutant fraction and total level of cfDNA positively correlated with tumor 
burden (p=0.026 and p=0.024). Finally, analysis of cfDNA at progression revealed 
novel mutations potentially affecting the MAPK pathway.
Conclusion: BRAFi combination therapies showed a response rate of 50% in BRAF 
V600E-mutated non-melanoma tumors. The fraction of BRAF-mutant cfDNA represent 
a sensitive indicator for clinical outcomes with plasma collected at week 4 and 12 as 
crucial time points for monitoring response and disease progression.
INTRODUCTION
Activating mutations in the BRAF gene are present 
in 5-10% of all human malignancies with the valine-
to-glutamic acid substitution at codon 600 (V600E) 
being the far most common mutation [1]. This mutation 
appears in a wide range of cancers including melanoma 
[2], colorectal cancer [3, 4], papillary thyroid cancer [5], 
non-small cell lung cancer [6, 7], hairy cell leukemia [8], 
and cholangiocarcinoma [9]. The introduction of specific 
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inhibitors of activated BRAF has greatly improved 
progression-free survival (PFS) and overall survival (OS) 
of patients with metastatic melanoma [10]. Dual inhibitor 
therapies have been successfully tested in malignant 
melanoma, where combining BRAF inhibitor (BRAFi) 
treatment with MEK inhibition (MEKi), improved PFS 
relative to those treated with BRAFi monotherapy [11] 
and similarly in colorectal cancer adding EGFR inhibitors 
(EGFRi) to BRAFi [12, 13]. The effect is however 
temporary as most tumors become resistant to therapy 
within 6 to 12 months [14, 15]. Consequently, close 
monitoring of therapy resistance is required but repeated 
access to tumor tissue is hampered by the invasive nature 
of tissue biopsies and the associated complications for the 
patients.
Circulating cell-free DNA (cfDNA) has the potential 
to monitor therapy response through a simple blood 
sample, often referred to as a liquid biopsy. Tumor specific 
mutations can be identified in cfDNA and hence presents 
a minimally-invasive strategy to assess tumor material. 
In solid tumors, cfDNA has shown great promise in 
cancer diagnosis, monitoring of therapy, and detection of 
therapy resistance and clonal evolution (reviewed in [16]). 
Furthermore, early cancer detection and tumor localization 
were recently demonstrated based on analyses including 
cfDNA [17]. In advanced malignant melanoma the BRAF 
V600E mutation can be detected in up to 84% of patients 
with mutation-positive tumors and the level of mutant 
DNA (cfBRAFV600E) has been shown to reflect response 
to targeted treatment including progression and tumor 
burden [18–20]. Most studies have focused on malignant 
melanoma and to some extent colorectal cancers [18, 21–
25], but little is known about the importance of circulating 
BRAF DNA in other cancers and how this information is 
related to BRAFi combination therapy.
In this study, we longitudinally measured the 
fraction of cfBRAFV600E in plasma samples collected 
every four weeks from baseline until disease progression 
from a heterogeneous group of advanced solid cancers 
included in the Copenhagen Prospective Personalized 
Oncology (CoPPO) project [26]. The aim was to study the 
dynamics in circulating BRAF DNA in response to BRAFi 
combination therapies (MEKi and EGFRi) and correlate 
these information’s to tumor characteristics and clinical 
outcomes. Furthermore, we performed exome sequencing 
of cfDNA collected at disease progression across cancer 
types to identify possible resistance mutations.
RESULTS
Patient characteristics
Mutant BRAF V600E was identified in tumor 
tissue (fresh biopsy n= 20, FFPE n= 3) in 5% of non-
melanoma CoPPO patients (23/455 patients) including 
colorectal (n=16), bile duct (n=4), lung (Non-Small Cell 
Lung Cancer, NSCLC) (n=2), and pancreatic cancers 
(n=1) (Figure 1). Seventeen patients started combination 
treatment with BRAFi/MEKi (lung and bile duct cancers) 
or BRAFi/EGFRi with or without irinotecan (colorectal 
cancer) (Figure 1 and Supplementary Table 2). Six patients 
never started treatment due to poor performance status and 
one patient requested early termination of treatment due 
to toxicity, and was therefore non-evaluable (NE). Sixteen 
patients were evaluable according to RECIST1.1 and 
cfDNA was collected at baseline and at least at 4 weeks 
after starting therapy from 12 of these patients. Four 
patients had either non-detectable cfBRAFV600E levels 
using ddPCR (allele fraction, AF < 0.001) or no plasma 
sample collected at baseline (Figure 1). The latter sample 
was excluded from the statistical analyses on baseline 
cfBRAFV600E levels (Figure 3). A total of 124 plasma 
samples were collected from the 16 evaluable patients 
with a mean number of 7.75 samples per patient.
Tumor response and progression
Thirteen of the 16 evaluable patients (81%) had 
reductions in their target tumor lesions on CT scans as 
shown by the waterfall plot (Figure 2A). Eight patients 
achieved an objective tumor response (CR n=1, PR 
n=7), seven had SD, and one had PD as best response 
according to RECIST 1.1. The median PFS and OS were 
4.8 and 15 months, respectively (Supplementary Figure 1). 
Additionally, the PFS ratio was >1.3 in nine patients which 
means that more than half of the patients experienced >30% 
longer PFS on BRAFi combinations compared to the most 
recent treatment (Supplementary Table 2). We also assessed 
the treatment response in plasma cfDNA and interestingly, 
changes in BRAF V600E AF compared to baseline, 
indicated tumor response (decrease in AF) and progression 
(increase in AF) at 4 and 12 weeks after commencing 
therapy, respectively (Supplementary Figure 2). In 
concordance with this observation, patients with a reduction 
in cfBRAFV600E AF less than 50% after 4 and 12 weeks 
had a significantly shorter OS and PFS compared to 
patients with a larger reduction (>50%) from baseline levels 
(Supplementary Figure 3). Although these analyses were 
statistically significant, the observations should be assessed 
in a larger cohort, to confirm the correlations between 
cfBRAFV600E reduction and survival.
To investigate whether cfDNA was an early marker of 
tumor progression, we defined progression as the time point 
when an increase in cfDNA was observed and compared 
to the date when progression was recorded according to 
RECIST 1.1. Fourteen patients had tumor progression 
according to RECIST1.1 within the study period. Increases 
in cfBRAFV600E AF preceded radiological evidence of 
progression in 11 out of 16 cases (median 5 weeks, range 
2-17 weeks, Figure 2B). The remaining patients were either 
progression-free at data cut-off (Pt2 and Pt12), had ND 
levels of cfBRAFV600E at RECIST-defined progression 
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(Pt3 and Pt10) or had unchanged BRAF AF at progression 
compared to baseline (Pt14). Longitudinal measurements of 
the mutant AF’s are presented for each of the 16 evaluable 
patients in Supplementary Figure 4.
Baseline plasma DNA
Baseline plasma samples were available from 
all BRAF-mutated patients except patient number 1 
(Pt1) where no plasma was available before treatment 
start (Figure 1 and Supplementary Table 2). Plasma 
cfBRAFV600E was detectable using ddPCR at baseline in 
81% (13/16) of the patients. The remaining three patients 
had undetectable levels of mutant BRAF (AF < 0.001) at 
baseline and at all measured time points during therapy 
(Pt 2, 3, 12, Supplementary Figure 4). The total cfDNA 
level per milliliter plasma (median 14.7 ng/ml, range 3.2 
- 175.5, n=16) and cfBRAFV600E AF (median AF 0.079, 
range ND – 0.39, n=16) indicated a correlation with tumor 
burden - defined as the sum of tumor measurements 
according to RECIST 1.1 (Spearman’s correlation 
coefficient, 0.55 and 0.56; P<0.05, Figure 3A and 3B). 
We further tested whether baseline cfBRAFV600E AF 
≥0.05 could predict OS and PFS as shown in a similar 
cohort [27]. Patients with a baseline mutant fraction ≥ 0.05 
showed a non-significant trend towards shorter OS and 
PFS (p=0.098 and p=0.065) compared to those with lower 
levels (Figure 3C and 3D). Similar results were observed 
when using the median cfBRAFV600E AF (0.08) as cut-
point (data not shown).
Resistance mechanisms
Characterizing tumor evolution in response to tar-
geted therapy is essential for understanding development 
of resistance. This study included a bile duct cancer patient 
(Pt5) who achieved a prolonged response, and exome 
sequencing was performed on three tissue and two plasma 
samples (Figure 4A–4B). The targeted BRAF mutation 
and a splice-site-disrupting TP53 mutation were present 
Figure 1: Study outline and baseline characteristics of patients with BRAF V600E mutated non-malignant melanoma 
tumors. Flow diagram (left) showing the number of patients with BRAF V600E- mutated tumors (n=23) and the number of patients with 
plasma samples collected for cfDNA analysis including baseline analyses (n=16) and longitudinal evaluation (n= 12, requiring a baseline 
sample and at least one plasma sample after therapy start). One patient was non-evaluable due to premature termination of therapy but 
the baseline plasma sample from this patient (*) was used for statistical analysis on baseline cfDNA levels. Characteristics of the patients 
with BRAF V600E-mutated tumors are shown in the table (right) including assigned therapy regimens. 1BRAF inhibitors administrated 
were vemurafenib 960 mg twice a day (BID) or dabrafenib 150 BID; 2MEK inhibitor was trametinib 2 mg daily (QD); 3EGRF inhibitors 
administrated were cetuximab 500 mg/m2 every 14 days or panitumumab 6 mg/kg intravenously (IV) every 14 days; 4Irinotecan was 
administrated at a dose of 180 mg/m2 every 14 days.
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in all samples analyzed indicating a dominant tumor 
clone characterized by these two pathogenic mutations. 
Baseline mutant fractions were higher in the solid and 
liquid baseline samples compared to the samples collected 
at progression, likely reflecting the reduced tumor size 
(Figure 4A). We observed tissue- and plasma-only variants 
(Figure 4B and Supplementary Table 3) likely illustrating 
low levels of cfDNA released from a specific tumor clone 
and the fact that tissue biopsies only represents a fraction 
of the heterogeneous tumor.
Longitudinal cfBRAFV600E monitoring was 
compared to images of the liver metastasis, the sum of 
measurable lesions and cancer antigen 19-9 (CA19-
9), and it was evident that, increases in the fraction of 
cfBRAFV600E indicated tumor growth >100 days (17 
weeks) prior to other measures (Figure 4A). Furthermore, 
whole exome sequencing (WES) and subsequent variant 
analysis was performedon three cfDNA samples collected at 
progression from patients with metastatic colorectal cancer 
(Pt7, 9, and 17). We identified three variants involved in the 
MAPK pathway (Figure 4C and Supplementary Table 3), 
which were present at the time of disease progression but 
not detectable in baseline tumor tissue samples.
DISCUSSION
Here we show that, the fraction of BRAF V600E 
in cfDNA can be used to monitor the response to BRAFi 
combination therapy in non-melanoma cancers and 
importantly, indicate disease progression median five 
weeks before radiological evidence. Longitudinal BRAF 
monitoring showed that, a reduction in AF at 4 and 12 
weeks after commencing treatment was significantly 
associated with longer PFS and OS, indicating that an 
early drop in cfBRAFV600E levels could be predictive of 
survival when monitoring advanced stage cancers using 
cfDNA. Of note, two patients with prolonged survival (Pt2 
and Pt12) had non-detectable (ND) cfBRAFV600E levels 
at baseline and throughout therapy indicating, that ND 
levels could be a possible prognostic marker as previously 
suggested [18, 24]. However, these observations are 
promising, larger cohort studies are needed to further 
validate the findings. Tumor responses were also evaluated 
according to RECIST1.1 and a response rate of 50% was 
achieved across tumor types with median PFS and OS of 
4.5 and 15 months, respectively, which are comparable 
with previous studies [13, 28, 29]. Interestingly, we 
observed a partial tumor response in both patients with 
NSCLC and a prolonged PFS and OS compared to 
previously reported (median PFS 9.7 months) [30].
Despite the small cohort, baseline measurements 
showed a positive correlation between tumor burden 
and the levels of total cfDNA and cfBRAFV600E AF. 
Furthermore, a high baseline BRAF-fraction indicated 
shorter OS and PFS, an observation that was in agreement 
with previous reports [21, 24, 25, 27, 31-34]. In addition, 
we observed a high concordance (83%) in BRAF-mutation 
status between tumor tissue and cfDNA possibly reflecting 
Figure 2: Tumor response and progression assessed by RECIST1.1 and cfDNA. (A) Waterfall plot showing the maximum 
%-change in target tumor lesions from baseline to best response according to RECIST1.1. Changes above 20% indicate PD, greater than 
-30% (line) indicates PR, changes between 20% and -30% indicates SD and tumor reduction of -100% indicate CR. Each patient (n=16) is 
designated by a colored bar representing the cancer types as shown in the legend. (B) Disease progression assessed by cfDNA (orange circles) 
and RECIST1.1 (blue triangles) for each patient (indicated by a colored horizontal line). The patient ID’s are indicated on the y-axis and 
the x-axis show PFS in weeks. The star symbols indicate the time of best response according to RECIST1.1 for the patients with PR or CR.
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the advanced disease status and the use of fresh biopsies 
instead of archival tumor material [35, 36]. Previous 
reports have shown a concordance ranging from 57-84% 
primarily from melanoma studies [12, 18, 20, 21, 24, 32, 
37, 38].
This cohort was ideal for evaluating 
cfBRAFV600E as a marker of therapy response and 
resistance in non-melanoma cancers, as the cohort 
included extensive plasma samples and most patients 
developed disease recurrence within a short timescale. 
However, our study had some limitations including 
a small cohort size, heterogeneity of cancer types and 
treatments. Furthermore, the non-invasive follow-up 
strategy included only the BRAF V600E mutation which 
is clinically relevant to only a subset of patients and 
complementary NGS analysis covering other cancer 
hotspot genes should be considered for early discovery 
of driver and resistance alterations.
Resistance to BRAFi therapy constitutes a major 
challenge and mutations leading to re-activation of the 
MAPK-pathway have been described in both malignant 
melanoma and colorectal cancers. Investigating a broad 
list of 278 MAPK-related genes in cfDNA collected at 
progression, identified 11 variants (including BRAF 
V600E), of which six where novel variants and five 
were previously described in e.g. the COSMIC database. 
Functional studies are needed to clarify the molecular 
effect of these variants. Patient Pt9 had a high frequency 
MEK1 variant (c.173A>C, p.Q58P, Table S3) located in 
a conserved region where several alterations have been 
reported in BRAFi-resistant melanoma samples [39] 
indicating that, this region might be involved in resistance 
Figure 3: Baseline cfDNA levels correlate with tumor size and survival. (A) A positive correlation was observed between the 
sum of target tumor measures according to RECIST 1.1 and total cfDNA levels and cfBRAFV600E allele fraction (B). The Spearman’s rank 
correlation coefficient was 0.55 (p= 0.026) and 0.56 (p= 0.024), respectively. Patients having both a CT scan and a baseline cfDNA sample 
were included (n=16). Cancer types are indicated by color as shown in the legend. High baseline ctBRAFV600E AF was correlated to 
shorter OS (C) (n=16, p= 0.098, log-rank test) and PFS (D) (n=16, P= 0.065, log-rank test) in patients with BRAF V600E-mutated cancers 
stratified on the level of baseline ctBRAFV600E AF threshold of 0.05 (5% allele frequency).
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but functional tests are required. Additionally, WES of 
multiple tissue and plasma biopsies from a bile duct 
cancer patient (Pt5) illustrated a dominant tumor clone 
characterized by a pathogenic TP53 mutation and the 
treatment target BRAF V600E detected in all solid and 
liquid biopsies, possibly explaining the good response 
observed for this patient. Interestingly, progression-only 
variants were identified in both tissue and plasma DNA but 
none of the variants were overlapping, possibly illustrating 
the challenges associated with tumor clonality or differences 
in sequencing depth and thus allele frequency.
In conclusion, our study indicates that BRAFi 
combination therapy is effective in advanced, solid 
non-melanoma BRAFV600E-mutated cancers and 
cfBRAFV600E may be used as an early indicator of 
response and progression.
Figure 4: Monitoring tumor response and MAPK-related mutations in response to BRAFi combination therapy. Panel 
(A) illustrates the tumor response in a bile duct cancer patient (Pt5). At the top, the tumor response assessed by CT scans marking the area 
with liver metastasis (blue marking). Below, the changes in the sum of target tumor lesions according to RECIST 1.1(green line), CA19-9 
levels (red line) and cfBRAFV600E AF (blue line) are shown. The x-axis indicates the time from therapy start (day 0) until collection of 
the last plasma sample (day 321) including the day of therapy termination due to progression (day 286, end of grey shading). The primary 
y-axis indicates the BRAF V600E AF and the secondary y-axis shows both the CA19-9 level (presented as divided by 1000 due to an 
extreme baseline value of >16000) and the sum of measurable tumor lesions according to RECIST 1.1. Panel (B) shows the MAPK-
associated variants identified in the three tissue biopsies (green table) and the two plasma samples (blue table). Due to the difference in 
sequencing depth and therefore mutation fraction cut-offs (tissue AF ≥ 0.10, plasma AF ≥0.02) we were not able to directly compare tissue 
with plasma mutations. Table (C) summarizes the progression-only MAPK-related variants together with the BRAF V600E mutation 
identified in cfDNA from three colorectal cancer patients with early progression and a high baseline cfBRAFV600E AF.
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MATERIALS AND METHODS
Patients and sample collection
Fresh tumor biopsies were collected and molecularly 
characterized in the CoPPO study (NCT02290522) as 
previously described [26]. Formalin-fixed paraffin-
embedded (FFPE) archival tumor tissue or plasma cfDNA 
was examined in cases where tumors were non-accessible 
for biopsy. All patients had metastatic solid tumors and 
exhausted treatment options. Studies were conducted 
in accordance with the Declaration of Helsinki and 
written informed consent was obtained for all patients 
(Danish Ethical Committee, file number: 1300530). 
Patients were allocated to targeted treatment according 
to recommendations made by a multidisciplinary tumor 
board. Computed Tomography (CT) scans were performed 
every eight weeks and tumor responses were evaluated 
according to Response Evaluation Criteria In Solid 
Tumors (RECIST) 1.1 [40] and classified as complete 
response (CR), partial response (PR), stable disease (SD) 
or progressive disease (PD). The PFS ratio was calculated 
as PFS on BRAFi combination treatment divided by PFS 
on most recent treatment. A PFS ratio >1.3 was reported 
because an improvement in PFS > 30% has been described 
to be a clinical meaningful cut-off [41]. Plasma samples 
for cfDNA analysis were collected immediately before 
treatment initiation (within 24h), longitudinally every four 
weeks, and if possible, at progression or after treatment 
termination.
DNA extraction and quantification
Peripheral blood was collected in BCT tubes (Streck 
Laboratories, Omaha, NE, USA) as previously described 
[42]. Circulating DNA was extracted from 2-4 ml plasma 
using the QIAsymphony Circulating DNA Kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s 
instructions using an elution volume of 60 μl. Extracted 
cfDNA was stored at -20°C until further use. DNA 
quantification was performed using a dsDNA HS Assay 
Kit (Thermo Fisher Scientific, Waltham, MA) on a Qubit 
Fluorometer (Thermo Fisher Scientific, Waltham, MA) 
and the concentration of cfDNA per milliliter of plasma 
was calculated for each time point.
Droplet digital PCR
Mutant BRAF V600E was quantified using the 
QX200 droplet digital PCR (ddPCR) system from 
Bio-Rad (Bio-Rad/Molecular MD, California, USA). 
Dual labeled (FAM or HEX) fluorescent probes for 
BRAF V600E and the wild type loci were used (Bio-
Rad, V600E; cat no. 10031246 dHsaCP2000027, WT 
for V600E; cat no. 10031249 dHsaCP2000028). PCR 
reaction mixtures were run and subsequently analyzed 
using the QX200 reader, according to manufactures 
instructions. The mutant allele fraction (AF, mutant 
counts/total DNA counts (mutant + wild type)) was 
estimated using QuantaSoft v.1.7.4 software from 
Bio-Rad. Mutant AFs ≥0.001 (0.1%) were detected 
requiring three or more mutation-positive droplets per 
well as recommended by the company. An increase in 
cfBRAFV600E AF was recorded if the AF increased 
from non-detectable to detectable levels (AF ≥ 0.001) 
or increased in two consecutive samples unless it was 
the last plasma sample collected prior to termination of 
treatment due to clinical progression.
Exome sequencing
Whole exome sequencing was performed on 
plasma cfDNA samples (Pt5, 7, 9 and 17) obtained 
at disease progression from patients with a high AF 
of cfBRAFV600E. Patient tumor samples were also 
analyzed by WES as part of the CoPPO study [26]. 
DNA libraries were constructed from 10 ng cfDNA 
using NEBNext Ultra II DNA Library Prep kit for 
Illumina protocols (version July 2016, New England 
Biolabs). Hybridization-based exome capture was 
performed according to the manufacturer’s instructions 
using the SeqCap EZ MEDExome (Roche NimbleGen 
Inc.). The samples were pooled and sequenced on the 
Illumina NextSeq platform to a minimum average 
coverage >50 x. Analysis of WES data from both tumor 
tissue DNA and cfDNA was performed using the same 
pipeline including the Qiagen software Biomedical 
Genomics Workbench version 3.0 and Ingenuity Variant 
Analysis version 5.1. Briefly, confident calls originating 
from bidirectional sequence reads were filtered by a 
phred quality score ≥30, read depth of ≥20, and allele 
frequency ≥5%. Tumor-specific variants were selected 
by subtracting the germline variants which were 
available through the CoPPO project [26]. Ingenuity 
Variant Analysis was used to identify coding or splice 
site disrupting variants (+/- 2 base pairs from exon-
intron boundaries). Common variants reported with 
an allele frequency >1% in the 1000 genomes project, 
the NHLBI ESP exomes, or the ExAC frequency 
were removed, unless the variant was established as a 
common pathogenic variant according to the Ingenuity 
Knowledge database. Variant analysis was broadly 
focused on the MAPK pathways using a comprehensive 
gene list from Gene Set Enrichment Analysis (GESA) 
including genes from the classical MAP kinase pathway 
as well as the JNK/p38 and ERK5 pathways (M10792; 
KEGG_MAPK_SIGNALING_PATHWAY) [43, 44]
(Supplementary Table 1). In addition, an extended 
list of cancer-associated variants identified by exome 
sequencing is included in (Supplementary Table 4). The 
variant lists were generated using the Ingenuity Variant 
Analysis software.
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Statistical analyses
Overall survival (OS) and PFS was estimated 
using Kaplan-Meier statistics [45] and a log-rank test 
was used to compare OS and PFS among patient groups. 
PFS was defined, as the time from treatment start to 
disease progression (according to RECIST 1.1 or clinical 
evaluation) or death. Overall survival was defined as the 
time from treatment start to date of death. Patients that 
were progression-free or still alive at the day of data 
cut-off (24 October 2017) were censored in the survival 
analyses. The Spearman rank correlation analysis was 
used to compare tumor and plasma measures. All analyses 
were two-sided, and P-values <0.05 were considered 
statistically significant. Statistical analyses were 
performed using IBM Statistics SPSS (version 22) and R 
(version 0.99.903).
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